measles and rubella vaccine / Generic mfg. - LARVOL DELTA

SHIELD: Strengthening HPV Immunization Through EPI Leveraged Delivery (clinicaltrials.gov) - P2 | N=115 | Not yet recruiting | Sponsor: International Vaccine Institute

New P2 trial • Oncology

Mumps Virus: Replication, Immune Response, and the Changing Landscape of Vaccine Effectiveness. (PubMed, Pathogens) - "The mumps vaccine, now included in combination with measles and rubella vaccines (MMR), was first made available in the 1960s...We review current epidemiological data, highlighting shifts in MuV transmission and genotype distribution, and discuss the need for updated or genotype-matched vaccines. By connecting molecular virology with real-world trends in disease spread and vaccine performance, this review aims to support ongoing efforts to strengthen mumps control strategies and inform the development of next-generation vaccines."

Journal • Review • CNS Disorders • Infectious Disease • Measles • Mumps • Otorhinolaryngology • Rubella

Investigation of a measles outbreak in Brondong subdistrict, Lamongan district, Indonesia, 2023. (PubMed, Western Pac Surveill Response J) - "The measles outbreak was attributed to a decline in immunization coverage, particularly for the second dose of the measles-rubella vaccine. This decrease was driven by multiple factors, including the impact of the COVID-19 pandemic, misconceptions related to religious beliefs, and the long interval between the first and second vaccine doses, which contributed to the patients who were lost to follow-up. Collectively, these factors increased the vulnerability of children to measles infection."

Journal • Retrospective data • Infectious Disease • Measles • Novel Coronavirus Disease • Rubella

Low-dose yellow fever vaccination in infants: a randomised, double-blind, non-inferiority trial. (PubMed, Lancet) - P4 | "Compared with the standard yellow fever vaccine dose, a dose of 500 IU did not meet the non-inferiority criterion, suggesting that minimum dose requirements in adults are not generalisable to infants. Therefore, standard yellow fever doses should be used for infants in the routine WHO Expanded Programme on Immunization."

Head-to-Head • Journal • Infectious Disease • Measles • Rubella

Hybrid microneedle patch for administration of measles and rubella vaccine with an on-patient medical record. (PubMed, J Control Release) - "Immunogenicity studies in cotton rats confirmed that neutralizing antibody titers were similar after measles vaccination by hybrid MNPs (containing NIR particles), conventional MNPs (without NIR particles) and subcutaneous injection. These findings suggest that hybrid MNPs enable co-administration of vaccines and NIR particles for OPMR or co-delivery of other materials requiring sequestration."

Journal • Infectious Disease • Measles • Rubella

The Effects of Iron Treatment on Malaria and Measles Vaccine Response in Kenyan Infants With Iron Deficiency (clinicaltrials.gov) - P=N/A | N=324 | Not yet recruiting | Sponsor: Nicole Stoffel | Trial completion date: Dec 2027 ➔ Apr 2028 | Initiation date: Jul 2025 ➔ Jan 2026 | Trial primary completion date: Sep 2027 ➔ Dec 2027

Trial completion date • Trial initiation date • Trial primary completion date • Hematological Disorders • Infectious Disease • Malaria • Measles

A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (clinicaltrials.gov) - P2 | N=200 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed

Trial completion

A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (clinicaltrials.gov) - P1 | N=551 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed

Trial completion

Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 study. (PubMed, Lancet Glob Health) - "These data show that EuTCV Vi-CRM197 is immunologically non-inferior to Typbar TCV in infants 28 days after vaccination and that the overall safety and reactogenicity profiles in healthy infants, children, and adults studied in Kenya and Senegal were similar to Typbar TCV. These data support WHO prequalification."

Clinical • Head-to-Head • Journal • P3 data • Infectious Disease • Measles • Rubella

Immunogenicity and Safety Results of a Randomized, Three-Arm, Phase IV Clinical Trial of Concomitant Administration of Typhoid Vi Conjugate Vaccine with Measles and Rubella Vaccine in Healthy Infants. (PubMed, Viruses) - "Most adverse events were mild, and only one serious adverse event was reported. These findings support the co-administration of TCV and MR vaccine as a safe and effective strategy."

Clinical • Journal • P4 data • Infectious Disease • Measles • Rubella

A post-marketing safety surveillance study on vaccines in Chongqing, China from 2006 to 2021: Using a nationwide spontaneous reporting database with multiple data mining methods. (PubMed, Hum Vaccin Immunother) - "Allergic reactions were the most prevalent, with 2,743 cases (88.2% of the RAR), and the Measles-Rubella Vaccine (MR) had the highest IR of allergic reactions, reaching 267.1 cases per 100,000 doses administered...The overall safety of vaccines in Chongqing is satisfactory. Vaccine manufacturers should optimize the production process to enhance vaccine tolerability."

Journal • P4 data • Allergy • Cardiovascular • Infectious Disease • Measles • Rubella

High measles and rubella vaccine coverage and seroprevalence among Zambian children participating in a measles and rubella supplementary immunization activity. (PubMed, PLOS Glob Public Health) - "Although children vaccinated during this SIA were highly likely to have previously received routine vaccinations, the SIA reached a considerable number of susceptible children. Monitoring SIA effectiveness and efficiency through standardized metrics and formats is critical for impactful vaccine delivery strategies."

Journal • Infectious Disease • Measles • Rubella

A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (clinicaltrials.gov) - P2 | N=200 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting

Enrollment closed

Infant Malaria Vaccine Schedule Optimization (clinicaltrials.gov) - P2 | N=1200 | Recruiting | Sponsor: PATH | Trial completion date: Nov 2027 ➔ Mar 2028 | Trial primary completion date: Nov 2027 ➔ Mar 2028

Trial completion date • Trial primary completion date • Infectious Disease • Malaria

The Effect of Implementing Advanced Strategies to Improve Immunization Coverage in the Elogbele Health Area. (PubMed, Cureus) - "This study has demonstrated the importance of implementing advanced strategies and enabled health workers in the Elogbele health area to strengthen their immunization capabilities, improve immunization coverage, and catch up with the number of unimmunized children."

Journal • Infectious Disease • Measles • Rubella

Infant Malaria Vaccine Schedule Optimization (clinicaltrials.gov) - P2 | N=1200 | Recruiting | Sponsor: PATH | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Malaria

The Effects of Iron Treatment on Malaria and Measles Vaccine Response in Kenyan Infants With Iron Deficiency (clinicaltrials.gov) - P=N/A | N=324 | Not yet recruiting | Sponsor: Swiss Federal Institute of Technology | Initiation date: Mar 2025 ➔ Jul 2025

Trial initiation date • Hematological Disorders • Infectious Disease • Malaria • Measles

Cross-sectional study of vaccine coverage among children aged 1 to 24 months in Opuwo District, Kunene region, Namibia. (PubMed, BMC Public Health) - "In our study, we analyzed the children's immunization status regarding the oral/inactivated polio vaccine, pneumococcal vaccine, rotavirus vaccine, measles and rubella vaccine and a pentavalent vaccine that prevents five types of diseases, including diphtheria, pertussis, tetanus, hepatitis B, and haemophilus influenzae type b. Results showed that during 2019-2020, at least 57.2% of the antigens reached the recommended coverage of over 80% in Opuwo District...Other factors included residing far from the health facilities, lack of funds to cater for transport as well lack of knowledge as to when the child was due for immunization were found to be reasons of unvaccinated or partially immunized. Such factors contributing to immunization rate of children should be highlighted and policies to educate the caretaker of children should be considered and enforced, in order to further increase immunization rate of children in relatively less developed areas."

Journal • Observational data • Hepatitis B • Infectious Disease • Inflammation • Influenza • Measles • Pertussis • Pneumococcal Infections • Respiratory Diseases • Rotavirus Infections • Rubella • Tetanus

Coverage and predictors of full measles-rubella immunization among children aged 24-59 months in Northern Ghana: a post measles outbreak assessment. (PubMed, BMC Public Health) - "The uptake of the second dose of the measles-rubella vaccine in Northern Ghana was below the recommended 95% by the WHO. Awareness of the vaccine, knowledge level, ANC attendance, receiving other vaccines, and perceived side effects were the main predictors of measles vaccine uptake in the region. Ghana Health Service should intensify sensitization and awareness creation at the community level."

Journal • Infectious Disease • Measles • Rubella

Immunization status of children with cerebral palsy: A cross-sectional hospital-based study in Vietnam. (PubMed, PLoS One) - "This is the first study to document the immunization status of children with CP in Vietnam. A large proportion had not received the measles-rubella vaccine and 17.3% were not fully immunized. To increase vaccination coverage, interventions and strategies are required to ensure that all children with CP have equitable access to early diagnosis, immunization, health education programs, outreach programs, and frequent follow-up. Early diagnosis and focused intervention in early life could further improve vaccination coverage in children with CP."

Journal • Cerebral Palsy • CNS Disorders • Epilepsy • Infectious Disease • Measles • Pediatrics • Rubella

Safety and immunogenicity of Biological E's typhoid conjugate vaccine TYPHIBEVⓇ concomitantly administered with measles rubella vaccine: a phase IV prospective, multicenter study. (PubMed, IJID Reg) - "No safety signals were identified during this study and no immunogenic inference was seen when TYPHIBEV was co-administered with MR. CTRI/2022/02/040285."

Clinical • Journal • P4 data • Infectious Disease • Measles • Pain • Rubella

Childhood vaccination trends among the Maasai nomadic pastoralists: Insights from a community-based vaccine registry in Kenya. (PubMed, PLOS Glob Public Health) - "The Measles-Rubella vaccine had the highest dropout rate (64.66%) between its two doses, largely due to delays in administering the second dose at 18 months...The study confirmed that community level estimates were significantly below the national immunization targets. Understanding factors affecting coverage, timeliness and dropout rates at this level is important for building a strong and sustainable vaccine ecosystem for hard-to-reach communities."

Journal • Infectious Disease • Measles • Pneumococcal Infections • Rubella

Infant Malaria Vaccine Schedule Optimization (clinicaltrials.gov) - P2 | N=1200 | Not yet recruiting | Sponsor: PATH

New P2 trial • Infectious Disease • Malaria

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial. (PubMed, Lancet) - P3 | "When compared with a licensed, quadrivalent meningococcal conjugate vaccine, and given alongside other routine vaccines, a single dose of NmCV-5 was safe and elicited a non-inferior immune response in infants aged 9 months and young children aged 15 months."

Head-to-Head • Journal • P3 data • CNS Disorders • Infectious Disease • Measles • Meningococcal Infections • Rubella

A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (clinicaltrials.gov) - P1 | N=552 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting | Phase classification: P1/2 ➔ P1

Enrollment closed • Phase classification